Results 211 to 220 of about 44,670 (231)

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

New England Journal of Medicine, 2016
James N Ingle, Julie R Gralow, Karen A Gelmon   +2 more
exaly  

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Journal of Clinical Oncology, 2008
Stephen K L Chia, Frédéric Amant, John F R Robertson   +2 more
exaly  

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Lancet Oncology, The, 2013
Kwok-Leung Cheung, Andrew M Wardley, Anthony Howell, Howell A, Howell T   +2 more
exaly  

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncology, The, 2019
Eleftherios P Mamounas, Jong-Hyeon Jeong, Adam M Brufsky   +2 more
exaly  

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

Journal of Clinical Oncology, 2008
Rowan T Chlebowski
exaly  

Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Lancet Oncology, The, 2017
Irene E G Van Hellemond, Judith R Kroep, Sabine C Linn   +2 more
exaly  

Aromatase

2016
openaire   +1 more source

Aromatase

2012
openaire   +1 more source

SWITCH TO AROMATASE INHIBITOR BETTER THAN CONTINUING TAMOXIFEN

Ca-A Cancer Journal for Clinicians, 2005
exaly